Virtus ETF Advisers LLC Denali Therapeutics Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 4,164 shares of DNLI stock, worth $89,234. This represents 0.06% of its overall portfolio holdings.

Number of Shares

4,164

Previous 4,092 1.76%

Holding current value

$89,234

Previous $95,000 27.37%

% of portfolio

0.06%

Previous 0.05%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$20.96 - $31.05 $1,509 - $2,235	72 Added 1.76%	4,164 $121,000
Q2 2024 Aug 14, 2024	BUY	$14.96 - $23.22 $5,340 - $8,289	357 Added 9.56%	4,092 $95,000
Q1 2024 May 15, 2024	SELL	$15.83 - $23.35 $4,099 - $6,047	-259 Reduced 6.48%	3,735 $76,000
Q4 2023 Feb 15, 2024	BUY	$16.2 - $23.18 $15,373 - $21,997	949 Added 31.17%	3,994 $85,000
Q3 2023 Nov 07, 2023	SELL	$20.63 - $30.17 $6,271 - $9,171	-304 Reduced 9.08%	3,045 $62,000
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $1,308 - $1,845	56 Added 1.7%	3,349 $98,000
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $27,584 - $41,131	-1,259 Reduced 27.66%	3,293 $75,000
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $8,488 - $10,956	-323 Reduced 6.63%	4,552 $126,000
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $934 - $1,387	36 Added 0.74%	4,875 $150,000
Q2 2022 Aug 12, 2022	BUY	$20.88 - $35.19 $29,357 - $49,477	1,406 Added 40.96%	4,839 $142,000
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $5,800 - $9,454	-200 Reduced 5.51%	3,433 $110,000
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $34,199 - $44,181	803 Added 28.37%	3,633 $162,000
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $7,271 - $11,734	-150 Reduced 5.03%	2,830 $143,000
Q2 2021 Aug 10, 2021	SELL	$50.3 - $78.44 $33,399 - $52,084	-664 Reduced 18.22%	2,980 $234,000
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $3,120 - $4,728	58 Added 1.62%	3,644 $208,000
Q4 2020 Feb 12, 2021	SELL	$36.89 - $93.56 $327,509 - $830,625	-8,878 Reduced 71.23%	3,586 $300,000
Q3 2020 Nov 13, 2020	SELL	$23.13 - $38.84 $39,552 - $66,416	-1,710 Reduced 12.06%	12,464 $447,000
Q2 2020 Aug 05, 2020	SELL	$16.01 - $28.82 $77,584 - $139,661	-4,846 Reduced 25.48%	14,174 $343,000
Q1 2020 May 14, 2020	SELL	$14.2 - $27.98 $39,547 - $77,924	-2,785 Reduced 12.77%	19,020 $333,000
Q4 2019 Feb 13, 2020	BUY	$14.4 - $19.99 $119,678 - $166,136	8,311 Added 61.59%	21,805 $380,000
Q3 2019 Nov 12, 2019	SELL	$15.32 - $21.92 $11,520 - $16,483	-752 Reduced 5.28%	13,494 $207,000
Q2 2019 Aug 13, 2019	BUY	$18.5 - $28.14 $19,332 - $29,406	1,045 Added 7.92%	14,246 $296,000
Q1 2019 May 14, 2019	SELL	$17.99 - $24.65 $28,586 - $39,168	-1,589 Reduced 10.74%	13,201 $307,000
Q4 2018 Feb 05, 2019	SELL	$13.88 - $21.75 $151,680 - $237,684	-10,928 Reduced 42.49%	14,790 $306,000
Q3 2018 Nov 14, 2018	SELL	$12.46 - $21.74 $235,481 - $410,864	-18,899 Reduced 42.36%	25,718 $559,000
Q2 2018 Aug 10, 2018	BUY	$15.25 - $21.02 $680,409 - $937,849	44,617 New	44,617 $680,000

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Denali Therapeutics Inc. Transaction History